Tauro-β-muricholic Acid-d4 (sodium salt)
(Synonyms: Tauro-β-muricholate-d4, TβMCA-d4) 目录号 : GC49012tauro-β-muricholic acid 定量的内标
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Tauro-β-muricholic acid-d4 (TβMCA-d4) is intended for use as an internal standard for the quantification of TβMCA by GC- or LC-MS. TβMCA is a competitive and reversible antagonist of the farnesoid X receptor (FXR; IC50 = 40 µM) and a taurine-conjugated form of the murine-specific primary bile acid β-muricholic acid .1 TβMCA accumulates in germ-free mice under normal conditions but is reduced after colonization with feces from a human donor.1,2 TβMCA is increased in the intestines of mice resistant to high-fat diet-induced obesity, fatty liver, and diabetes.3
1.Sayin, S.I., WahlstrÖm, A., Felin, J., et al.Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonistCell Metab.17(2)225-235(2013) 2.WahlstrÖm, A., Kovatcheva-Datchary, P., StÅhlman, M., et al.Induction of farnesoid X receptor signaling in germ-free mice colonized with a human microbiotaJ. Lipid. Res.58(2)412-419(2017) 3.Qi, Y., Jiang, C., Cheng, J., et al.Bile acid signaling in lipid metabolism: Metabolomic and lipidomic analysis of lipid and bile acid markers linked to anti-obesity and anti-diabetes in miceBiochim. Biophys. Acta.1851(1)19-29(2015)
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.846 mL | 9.2302 mL | 18.4604 mL |
| 5 mM | 0.3692 mL | 1.846 mL | 3.6921 mL |
| 10 mM | 0.1846 mL | 0.923 mL | 1.846 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。